1-8 of 8
Francisco J. Hernandez-Ilizaliturri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Myron S. Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M. Linton, Nina Wagner-Johnston, Randy D. Gascoyne, Graham W. Slack, Pierre Brousset, David A. Eberhard, Francisco J. Hernandez-Ilizaliturri, Gilles Salles, Thomas E. Witzig, Pier Luigi Zinzani, George W. Wright, Louis M. Staudt, Yandan Yang, P. Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D. Lewis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4127–4137.
https://doi.org/10.1158/1078-0432.CCR-16-2818
Published: 01 August 2017
View article titled, A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open the PDF for A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Matthew J. Barth, Cory Mavis, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4391–4397.
https://doi.org/10.1158/1078-0432.CCR-15-0056
Published: 30 September 2015
View article titled, Ofatumumab Exhibits Enhanced <em>In Vitro</em> and <em>In Vivo</em> Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma
Open the PDF for Ofatumumab Exhibits Enhanced <em>In Vitro</em> and <em>In Vivo</em> Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma in another window
Journal Articles

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

Ping-Chiao Tsai, Francisco J. Hernandez-Ilizaliturri, Naveen Bangia, Scott H. Olejniczak, Myron S. Czuczman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1039–1050.
https://doi.org/10.1158/1078-0432.CCR-11-1429
Published: 14 February 2012
View article titled, Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
Open the PDF for Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

Myron S. Czuczman, Scott Olejniczak, Aruna Gowda, Adam Kotowski, Arvinder Binder, Harman Kaur, Joy Knight, Petr Starostik, Julie Deans, Francisco J. Hernandez-Ilizaliturri
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1561–1570.
https://doi.org/10.1158/1078-0432.CCR-07-1254
Published: 03 March 2008
View article titled, Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global <em>CD20</em> Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Open the PDF for Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global <em>CD20</em> Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels in another window
Journal Articles

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

Scott H. Olejniczak, Francisco J. Hernandez-Ilizaliturri, James L. Clements, Myron S. Czuczman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1550–1560.
https://doi.org/10.1158/1078-0432.CCR-07-1255
Published: 03 March 2008
View article titled, Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
Open the PDF for Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression in another window
Includes: Supplementary data
Journal Articles

Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20

Sreeram Maddipatla, Francisco J. Hernandez-Ilizaliturri, Joy Knight, Myron S. Czuczman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4556–4564.
https://doi.org/10.1158/1078-0432.CCR-07-0680
Published: 01 August 2007
View article titled, Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20
Open the PDF for Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20 in another window
Journal Articles

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Beata Holkova, Edris Ottman, Myron S. Czuczman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5984–5992.
https://doi.org/10.1158/1078-0432.CCR-05-0577
Published: 22 August 2005
View article titled, Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model
Open the PDF for Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model in another window
Journal Articles

Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency Mouse Model

Francisco J. Hernandez-Ilizaliturri, Venkata Jupudy, Julie Ostberg, Ezogelin Oflazoglu, Amy Huberman, Elizabeth Repasky, Myron S. Czuczman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5866–5873.
Published: 15 December 2003
View article titled, Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency Mouse Model
Open the PDF for Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency Mouse Model in another window